Forteo no better than oral risedronate for back pain from vertebral fractures
This article was originally published in Scrip
Executive Summary
Eli Lilly reported that its bone-building anabolic drug Forteo (teriparatide [rDNA origin] injection) was no more effective than oral risedronate (Warner Chilcott's Actonel) in a Phase III clinical trial evaluating the relief of back pain for women with osteoporotic vertebral fractures.